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INTRODUCTION
Hepatocellular   carcinoma   (HCC)   is   one   of   the
major  cancers  in  the  world  with  a  mortality  of  more
than  250 000  cases  yearly.  More  than  137 000  cases
of HCC were diagnosed each year in China, which
acount  approximately  for  more  than  40  percent  of
the total number in the world. HCC has become the
second  major  cause  of  death  for  cancer  in  China
since  1990,  and  its  annual  mortality  is  expected  to
be  21.2  cases  per  100 000  population  in  the  year
2000.  Even  though  progresses  have  been  achieved
for  HCC  diagnosis  and  treat  ment,   its   5-year
mortality is still higher than 95 percent[1-3].
         The   prevalence   of   HCC   is   quite   different
among different areas around the world[4,5]. It is
considerably   high   in   South-East   Asia   and   sub-
Saharan  Africa,  particularly  in  some  southern  and
eastern regions inside China such as Fusui County in
Guangxi  Zhuang  Autonomous  Region  and  Qidong
City  in  Jiangsu  Province[6-9].  The  standardized
incidence  of  HCC  in  these  high-risk  regions  may
exceed 100 cases per 100000 of population[10]. The
obvious   difference   in   geographic   distribution   of
HCC  indicates  that  there  must  be  environmental
factors for its pathogenesis.
         Aflatoxin   B1   (AFB1),   which   is   produced   by
some  strains  of  Aspergillus  flavus,  is  a  potent
hepatotoxigen   and   hepatocarcinogen[11,12],   and   is
considered   as   a   major   cause   of   HCC   in   some
regions[13-18].   It   has   also   been   postulated   that
chronic infection with hepatitis B virus (HBV) in
combination with exposure to AFB1 in the diet may
contribute  to  the  extraordinary  high  risk  of  human
HCC  in  some  areas.  Actually,  two  case-control
studies in Shanghai have demo nstrated a strong
interaction  between  HBV  and  AFB1  for  risk  of
HCC[14,15 ].  A  similar  chemical-viral  interaction  has
been  observed  in  Taiwan[18-20].  The  synergism
between virus and mycotoxic carcinogen for the
development  of  human  HCC  suggests  that  reduction
in  both  risk  factors  may  bring  important  public
health consequences.
          The  concept  of  chemoprevention  of  cancer  is
over 40 years old and a number of works have been
done  in  this  field[21,22].  Looking  for  effective  and
safe   reagents   against   AFB1   and/or   other   HCC
related risk factors is one of the most important
chemoprote  ctive  strategies  for  HCC[23-26]. Green
tea was identified years ago as one of the effective
chemopreventive  reagents  against  HCC  through  a
series  of  animal  experiments  as  well  as  a  clinical
trial[27,28].    Recently    oltipraz,    another    preventive
agent  which  was  previously  described  as  a potent
inhibitor  of  AFB1  induced  hepatocarcinogenesis  in
rat[29-33],  has  been  shown  to   inhibit  the  bioactivation
of  aflatoxin  and  enhance  its  detoxification  in  a
clinical trial[34-37] as  well  as  in  human  hepatocytes  in
primary  culture[38].  Meanwhile,  a  universal  vaccination
program  against  HBV  that  started  a  decade  ago
now results in lower rates of HCC in children[39]. An
experimental  model  to  test  the  synergistic  effect  of
these  two  agents  and  their  prevention,  therefore,  is needed.
R E S E A R C H  O N  T R E E  S H R E W  M O D E L  O F
HEPATOCARCINOGENESIS
Tree  shrew  (Tupaia  spp.)  is  a  kind  of  small,
squirrel-like    mammals.  Formerly    it   was   considered
to   belong   to   the   Primate   order;   currently   it   is
classified into a separate order Scandentia and is
supposed  to  be  more  closely  related  to  human being
than   rodents[40,41].   They   have   been   used   in
biomedical  researches  since  as  early  as  the  1960s.
Many researches have been done on its visual and
nervous systems. In 1976, however, Reddy et al[42]
successfully  induced  liver  cancer  in  tree  shrew  by
AFB1.  Yan  et  al[43,44]  reported  that  tree  shrews  can
be  infected with HBV and they successfully used this
HBV-infected  tree  shrew  model  for  liver  cancer
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research.  Recently  Walter  et  al[45]  reported  their  in
vivo  and  in  vitro  study  results  from  tree  shrews
infected  with  HBV.  Yan  and  Li  reported   a
significantly  higher  incidence  of  HCC  in  tree  shrews
both  infected  with  human  HBV  and  exposed  to
AFB1  than  with  either  agent  alone[46,47].  Thus,  this
tree shrew model appears to closely mirror the most
common causative factors of human HCC in some
prevalent  regions.  Furthermore,  with  the  exception
of  the  chimpanzee,  tree  shrew  is  the  only  known
animal  that  can  be  infected  with  human  HBV.
Therefore, the application of tree shrew in research
related  to  liver  cancer  and  hepatitis  is  receiving
increasing  attentions  and  a  number  of  works  have
been published[48-52].
         Because of the difficulties in raising tree shrews
artificially, most of the tree shrews used so far for
research  in  China  are  captured  individually  from
Yunnan  Province.  The  drawback  of  using   tree
shrews  captured  in  the  wild  for  animal  experiments
is  that  their  age,  health  status  and  reproductive
history are unknown. In an attempt to avoid this
drawback,   we   have   conducted   a   preliminary
experiment  on  rearing  tree  shrews  and  a  promising
result was obtained[53].
RESEARCH ON THE PREVENTIVE EFFECT OF OLTIPRAZ IN
TREE SHREW
In order to study the preventive effect of oltipraz on
AFB1  by  animal  models  other  than  rodents,  a  short-
term experiment was conducted on tree shrews.
        Male  and  female  adult  tree  shrews  (Tupaia
belangeri  chinensis)  were  purchased  from  the
Kunming   Institute   of   Zoology   (Yunnan   Province,
P.R. China).  Their  body  weights  ranged  from  100g
to  160g.  Upon  arrival,  1mL  blood  was  collected
from  each  animal  and  tested  for  HBV  markers
(HBsAg,  anti-HBsAg,  anti-HBcAg)  and  ALT.  The
tree shrews that were negative for these markers of
HBV  infection  and  that  had  ALT  value  below  55
units  were  divided  into  4  groups  with  6  or  7  animals
for  each  group.  Group  A:  normal  control;  group  B:
AFB1  alone;  group  C:  AFB1 + oltipraz  daily;  group
D: AFB1+oltipraz weekly. All the tree shrews were
allowed  1  week  to  acclimatize  to  the  facilities  prior
to the experiment. They were housed in separate,
suspended,   stainless   steel   wire   cages   under
controlled  environmental  conditions  with  a  12-hour
light/dark  photop  eriod.  They  had  free  access  to  tap
water and a natural ingredient diet.
         The experimental design is presented schemati-
cally in Figure 1. Tree shre ws in groups B, C and D
were  given  AFB1  (400µg/kg  b.w./day   in   liquid
milk)  daily  beginning   at  one  week  after   the
experiment  started  and  continued  for  4  weeks.  One
week  before  giving  AFB1,  tree  shrews  in  group  C
and      D      were      respectively      given      oltipraz
(0.5mmol/kg  b.w.)   daily   or   weekly,   by   gavage   in
a saturated solution of sucrose for 5 weeks. Blood
samples  and  24-hour  urine  samples  were  collected
once a  week  from  each  animal  throughout  the
experiment.  At  the  termination  of  the  9-week
experiment,  tree  shrews  were  killed  by  cervical
dislocation.  Three  blocks  of  liver  tissue  were  taken
from  each  animal.  Serial  sections  from  each  block
were  stained  histochemically  for  r-glutamyl
transpeptidase   (γ-GT)[54]  and  HE  respectively.  The
γ-GT  positive  liver  cells  were  counted  with  a  nest-
ruler  under  microscope.  The  results  were  analyzed
by  the  medical  statistics  analyzing  software  PEMS
that  was  designed  by  West  China  University  of
Medical  Sciences.  The  levels  of  aflatoxin-albumin
adducts   in   serum   samples   were   determined   by
radioimmune  assay[35]  and  the  levels  of  Aflatoxin-
N7-guanine adducts in urine samples were assayed by
HPLC[29].
        No γ-GT positive liver cell focus, a postulated
precancerous  marker[54-56] was  observed  in  any  liver
of the variously treated tree shrews in our study.
However,  different  numbers  of  γ-GT  positive  liver
cells,  which  scattered  mainly  around  the   portal
spaces,  were  observed  in  each  group.  Even  though
the  distribution  patterns  of  these  cells  were  similar
among   the   4   groups,   the   number    was   quite
different. Groups B and D had obviously less γ-GT
positive cells than groups A and C (Table 1).
        γ-GT normally exists in embryonic liver cell in
human  being  and  rat.  In  adult  rat,  it  exists  only  in
some  cells  around  portal  spaces[57 ] but  can  be  re-
expressed by mature hepatocytes during the recovery
process   after   liver   damage[58].   In   this   study   a
number of γ-GT positive hepatocytes presented in
periportal  regions  in  the  normal  control  group.  On
the   contrary,   the   number   of   γ-GT   positive
hepatocytes  of  the  same  sites  was  markedly  reduced
in  the  AFB1  treated  B  group.  This  phenomenon  is
fairly consistent with the findings on AFB1 induced
damage  in  rat,  in  which  the  periportal  hepatocytes
are  the  major  targets  of  AFB1.  As  shown  in  the
same    table,    the    number    of    γ-GT    positive
hepatocytes in group C was strikingly similar to the
normal  control  group.  This  result  indicates  strongly
the  preven  tive  action  of  oltipraz  against  AFB1
toxicity.  The  apparent  ineffectiveness  of  oltipraz in
group   D   is   most   possibly   due   to   its   inadequate
dose[59].  These  results  might  indicate  that  oltipraz
has the preventive was dose-related effect on AFB1.
           Insufficient  duration  and/or  insufficient  dosage
of  AFB1  treatment  may  result  in  that  no  separate
focus  of  γ-GT positive liv er cell formed at the end of
this  9-week  experiment[60].  However,  the  decrease
of   γ-GT   positive   hepatocytes   in   the   periportal
regions  may  be  an  early  marker  for  the  damage
induced by AFB1.
        The levels of both aflatoxin-albumin adducts in
serum  samples  and  aflatoxin-N7-guanine  adducts  in
urine   samples   of   the   tree   shrews   were   also
significantly affected by oltipraz. Following daily
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exposures  to  AFB1,  the  levels  of  serum  aflatoxin-
albumin adducts in group B increased rapidly over 2
weeks to reach a plateau that did not diminish until
cessation  of  AFB1  exposure.  In  group  C  however,
oltipraz attenuated the aflatoxin-albumin adducts
significantly  (P < 0.05)  with  a  median  reduction  of
80%.  The  mean  levels  of  aflatoxin-N7 -guanine  (ng/
mg  creatinine)  in  the  urine  samples  collected  at
week  5  were  6.34 ± 2.04  and  0.47 ± 0.13  in  groups
B   and   C   respectively.   This   93%   decrease
represented    a    statistically    significant    difference
(P<0.05).  These  results  were  reported  in  detail in
another   article[61].   The   major   mechanism   of
oltipraz’s   chemopreventive   effect   is   probably
through inducing the activities of cytochrome P450
system and phase 2 en zymes such as glutathione
transferases, epoxide hydrolase, etc, as reported by
Langouet et al[38]and Fahey et al[62].
Figure 1 Experimental design for animal treatment.
OLT: oltipraz; : all the animals were sacrificed.
Table 1 The number and size of γ-GT positive hepatocyte-group
   (x±sx)
Group  Treatment       No./cm2      mm2/cm2   mm2/No.
    A   Normal control  167.29±50.47    2.90±1.01    0.017±0.002
    B   AFB1    71.92±42.19a    1.14±0.69a   0.015±0.002
    C   AFB1+OLT daily  167.10±45.94c,d   2.73±0.87c,d 0.016±0.001
    D   AFB1+OLT weekly  83.66±34.94a    1.33±0.86a   0.015±0.002b
t   test:   aP < 0.05,   bP < 0.01,   vs   group   A;   cP < 0.01,   vs   group
B; dP<0.01, vs group
D. OLT: oltipraz;
No./cm2: the number of γ-GT positive hepatocyte-group per cm2
of liver tissue;
mm2/cm2: mm2 of γ-GT positive hepatocyte-group per cm2 of
liver tissue;
mm2/No.: mm2 of γ-GT positive hepatocyte-group per each one.
SUMMARY
Tree  shrew  is  phylogenetically  more  closely  related
to  human  being  than  ro  dents.  It  is  susceptible  both
to  HBV  infection  and  AFB1  intoxication.  It  is  a
suitable   experimental   animal   for   hepatocar-
cinogenesis. Attempt for its rearing is promising.
        Oltipraz is an effective reagent to protect AFB1
intoxication.  This  effect  is  proved  clearly  not  only
by histological examination, but also by reduction of
aflatoxin-albumin adducts in serum and aflatoxin-N7
guanine adducts in urine.
         All of these studies mentioned above provide a
foundation  for  further  HCC  chemop  revention  study
by using tree shrews in the future.
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